Karyopharm Therapeutics Inc. Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc.

KPTI

Rank in Stocks #33046
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already... Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
Share Price
$0.0286
Last synced: 2026-11-16
Market Cap
$827.63K
Change (1 day)
12.60%
Change (1 year)
-99.52%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Trade Karyopharm Therapeutics Inc. (KPTI)

Category

Healthcare
EPS for Karyopharm Therapeutics Inc. (KPTI)
EPS as of June 2026 TTM: $-22.32
According to Karyopharm Therapeutics Inc.'s latest financial reports, its current EPS (TTM) is $-22.32. At the end of 2025 the company had an EPS of $-17.93, a decrease compared to its 2024 EPS of $-9.41.
EPS history for Karyopharm Therapeutics Inc. from 2011 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-22.32 24.48%
2025 $-17.93 90.54%
2024 $-9.41 -49.92%
2023 $-18.79 -37.95%
2022 $-30.28 22.34%
2021 $-24.75 -39.44%
2020 $-40.87 -15.42%
2019 $-48.32 2.56%
2018 $-47.11 11.78%
2017 $-42.15 -3.77%
2016 $-43.80 -12.05%
2015 $-49.80 36.63%
2014 $-36.45 -56.53%
2013 $-83.85 946.70%
2012 $-8.01 54.09%
2011 $-5.20 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$15.66 -170.16%
US
$-7.07 -68.32%
US
$-5.29 -76.30%
AU
$12.73 -157.04%
BE
$21.56 -196.59%
NL

Questions about Karyopharm Therapeutics Inc.'s earnings per share (EPS)

What is Karyopharm Therapeutics Inc.'s earnings per share (EPS)?

Karyopharm Therapeutics Inc.'s earnings per share (EPS) over the last twelve months is $-22.32, as of Jun 2026.

What was Karyopharm Therapeutics Inc.'s earnings per share (EPS) in 2025?

In 2025, Karyopharm Therapeutics Inc.'s earnings per share (EPS) was $-17.93, compared with $-9.41 in 2024.

How has Karyopharm Therapeutics Inc.'s earnings per share (EPS) changed since 2020?

From 2020 to 2025, Karyopharm Therapeutics Inc.'s earnings per share (EPS) was highest in 2024 ($-9.41) and lowest in 2020 ($-40.87).

How does Karyopharm Therapeutics Inc.'s earnings per share (EPS) compare with similar companies?

Karyopharm Therapeutics Inc.'s earnings per share (EPS) ($-22.32) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.